Literature DB >> 7638327

The cost of a preventable disease: estimated U.S. national medical expenditures for congenital syphilis, 1990.

G de Lissovoy1, J Zenilman, K E Nelson, F Ahmed, D D Celentano.   

Abstract

Reported cases of congenital syphilis have increased rapidly in recent years. The purpose of this study was to estimate first-year medical care expenditures among 1990 incident cases of infants diagnosed with congenital syphilis. The authors used a synthetic estimation model to calculate expenditures for congenital syphilis as the number of treated cases multiplied by cost per case. The number of cases was derived from surveillance data adjusted for underreporting and presumptive (false-positive) treatment. Cost per case was based on expected hospital and physician charges applied to case treatment protocols appropriate to case severity. Base-case estimated first-year medical expenditure for 1990 treated cases (N = 4,400) in 1990 was +12.5 million. In sensitivity analysis, estimates ranged from +6.2 million to +47 million. Substantial reduction in congenital syphilis treatment costs could be achieved through targeted public health interventions consisting of prenatal maternal screening and contact tracing of males testing positive for syphilis. Physicians should be aggressive in presumptive treatment of newborns, since this usually prevents future disability but represents a small portion of total national expenditure for congenital syphilis. More precise data on severe cases resulting in long-term disability are needed to make reliable cost estimates.

Entities:  

Mesh:

Year:  1995        PMID: 7638327      PMCID: PMC1382149     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  16 in total

1.  The effects of case definition in maternal screening and reporting criteria on rates of congenital syphilis.

Authors:  D A Cohen; D Boyd; I Prabhudas; L Mascola
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

2.  Congenital syphilis: reporting and reality.

Authors:  P N Zenker; S M Berman
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

3.  Evaluation and treatment of congenital syphilis.

Authors:  M K Ikeda; H B Jenson
Journal:  J Pediatr       Date:  1990-12       Impact factor: 4.406

4.  Transplacental passage of erythromycin and clindamycin.

Authors:  A Philipson; L D Sabath; D Charles
Journal:  N Engl J Med       Date:  1973-06-07       Impact factor: 91.245

5.  Screening for syphilis in pregnancy: an assessment of the costs and benefits.

Authors:  K Williams
Journal:  Community Med       Date:  1985-02

6.  Epidemiology of primary and secondary syphilis in the United States, 1981 through 1989.

Authors:  R T Rolfs; A K Nakashima
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

7.  Economic evaluation of maternal screening to prevent congenital syphilis.

Authors:  B Stray-Pedersen
Journal:  Sex Transm Dis       Date:  1983 Oct-Dec       Impact factor: 2.830

8.  Is antenatal screening for syphilis worth while?

Authors:  S M Garland; V N Kelly
Journal:  Med J Aust       Date:  1989-10-02       Impact factor: 7.738

9.  Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team.

Authors:  B R Edlin; K L Irwin; S Faruque; C B McCoy; C Word; Y Serrano; J A Inciardi; B P Bowser; R F Schilling; S D Holmberg
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

10.  Serological screening tests for syphilis in pregnancy: results of a five year study (1983-87) in the Oxford region.

Authors:  P Bowell; K Mayne; A Puckett; C Entwistle; J Selkon
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

View more
  1 in total

1.  Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States.

Authors:  Harrell W Chesson; Dayne Collins; Kathryn Koski
Journal:  Cost Eff Resour Alloc       Date:  2008-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.